SCHEMBL13615441

SCHEMBL13615441

COC(=O)c1c(C)noc1-c1cccc(OC)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.54
PTGS1 P23219 1/20 0.52
ALDH1A1 P00352 5/20 0.50
HPGD P15428 2/20 0.50
MAPT P10636 5/20 0.49
HSD17B10 Q99714 2/20 0.49
LMNA P02545 1/20 0.49
SMN1; SMN2 Q16637 3/20 0.48
TDP1 Q9NUW8 1/20 0.47
KDM4E B2RXH2 1/20 0.46
MAPK1 P28482 1/20 0.46
VDR P11473 3/20 0.46
ESR1 P03372 1/20 0.46
THRA P10827 1/20 0.46
THRB P10828 1/20 0.46
RXRA P19793 1/20 0.46
PPARG P37231 1/20 0.46
PPARD Q03181 1/20 0.46
PPARA Q07869 1/20 0.46
ESR2 Q92731 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4333981 0.88 ALDH1A1 (0.58) HTTALDH1A1HPGDMAPTHSD17B10
SCHEMBL4035250 0.86 HTT (0.57) HTTPTGS1ALDH1A1MAPTHSD17B10
SCHEMBL3709582 0.84 HTT (0.54) HTTPTGS1ALDH1A1MAPTSMN1; SMN2
SCHEMBL13615438 0.84 HTT (0.54) HTTPTGS1ALDH1A1LMNANPC1
SCHEMBL17736161 0.83 ALDH1A1 (0.56) HTTPTGS1ALDH1A1HPGDMAPT
SCHEMBL16502243 0.83 PTGS1 (0.73) HTTPTGS1ALDH1A1HPGDMAPT
SCHEMBL13438 0.81 PTGS1 (0.69) HTTPTGS1ALDH1A1MAPTLMNA
SCHEMBL5730122 0.77 HPGD (0.58) HTTPTGS1ALDH1A1HPGDHSD17B10
SCHEMBL3703021 0.77 HTT (0.52) HTTPTGS1ALDH1A1MAPTKDM4E
SCHEMBL2288595 0.76 HTT (0.54) HTTPTGS1ALDH1A1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612069-B2 Acyl guanidines as beta-secretase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2009-11-03 US disclosed
US-7612069-B2 Acyl guanidines as beta-secretase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2009-11-03 US disclosed
US-7273882-B2 Aminoacetamide acyl guanidines as β-secretase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-09-25 US disclosed
US-7273882-B2 Aminoacetamide acyl guanidines as β-secretase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-09-25 US disclosed
US-20070015754-A1 Acyl guanidines as beta-secretase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-01-18 US disclosed
US-20070015754-A1 Acyl guanidines as beta-secretase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015754-A1 Acyl guanidines as beta-secretase inhibitors BACE1, APP, BACE2 HTT 453/4885PTGS1 782/4885ALDH1A1 2144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.